Product Information
ACETAMINOPHEN 650 MG SUPPOS is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $0.3494 per EA under NDC 45802073000. Its NADAC has been published 474 times since Sep 6, 2017.
FDA first approved this application on Dec 1, 1986.
The High Outlier badge above means this manufacturer's average price in the Acetaminophen market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
650 mg/1
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802073000
Classification
Generic
Dosage Form
SUPPOSITORY
Route
RECTAL
Effective Date
9/23/2026
Active Ingredients
ACETAMINOPHENApproval Type
Generic (ANDA)
FDA Application
ANDA070608FDA Approved
12/1/1986
On Market Since
10/28/2010
Price Statistics
The NADAC for ACETAMINOPHEN 650 MG SUPPOS has been published 474 times since Sep 6, 2017, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3494 per EA |
|---|---|
| All-time high | $0.3731 (Mar 14, 2018) |
| All-time low | $0.2796 (Dec 20, 2017) |
| 52-week high | $0.3494 |
| 52-week low | $0.3340 |
| Median price | $0.3390 |
| Average price | $0.3355 |
| Largest weekly change | +28.1% (Jan 17, 2018) |
| Weeks tracked | 474 |
| Tracking since | Sep 6, 2017 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 1% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Acetaminophen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ACETAMINOPHEN 650 MG SUPPOS?
The current National Average Drug Acquisition Cost (NADAC) for ACETAMINOPHEN 650 MG SUPPOS, manufactured by Padagis Israel Pharmaceuticals Ltd, is $0.3494 per EA (NDC 45802073000), effective Sep 30, 2026.
How has the price of ACETAMINOPHEN 650 MG SUPPOS changed over time?
Over the history we have for it, the NADAC for ACETAMINOPHEN 650 MG SUPPOS has held within roughly two percent of its current level. It has been tracked across 474 weekly CMS publications since Sep 6, 2017.
What are the highest and lowest recorded NADAC prices for ACETAMINOPHEN 650 MG SUPPOS?
Since Sep 6, 2017, the NADAC for ACETAMINOPHEN 650 MG SUPPOS has ranged from a low of $0.2796 (Dec 20, 2017) to a high of $0.3731 (Mar 14, 2018), with a median of $0.3390 per EA.
Are there cheaper alternatives to ACETAMINOPHEN 650 MG SUPPOS?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ACETAMINOPHEN 650 MG SUPPOS, is $0.3466 per EA — about 1% below ACETAMINOPHEN 650 MG SUPPOS.
Who manufactures ACETAMINOPHEN 650 MG SUPPOS?
ACETAMINOPHEN 650 MG SUPPOS (NDC 45802073000) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.